References
Colomb-Cotinat M, Lacoste J, Brun-Buisson C et al (2016) Estimating the morbidity and mortality associated with infections due to multidrug-resistant bacteria (MDRB), France, 2012. Antimicrob Resist Infect Control 5:56. https://doi.org/10.1186/s13756-016-0154-z
Bassetti M, Poulakou G, Ruppe E et al (2017) Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. Intensive Care Med. https://doi.org/10.1007/s00134-017-4878-x
Guggenbichler J, Kofler J, Allerberger F (1985) The influence of third-generation cephalosporins on the aerobic intestinal flora. Infection 13:S137–S139
Grohs P, Kerneis S, Sabatier B et al (2014) Fighting the spread of AmpC-hyperproducing Enterobacteriaceae: beneficial effect of replacing ceftriaxone with cefotaxime. J Antimicrob Chemother 69:786–789. https://doi.org/10.1093/jac/dkt403
McDonnell L, Armstrong D, Ashworth M et al (2017) National disparities in the relationship between antimicrobial resistance and antimicrobial consumption in Europe: an observational study in 29 countries. J Antimicrob Chemother 72:3199–3204. https://doi.org/10.1093/jac/dkx248
Author information
Authors and Affiliations
Contributions
BKT, EV, JRZ, LT, and MH contributed substantially to the conception and design of the study. BKT, EV, CPo, LP, CPa, PM, CH, and PP performed the data acquisition. BKT, KAB, and MH analyzed the data. BKT, EV, JRZ, CPo, CPa, KAB, LT, and MH interpreted the data. BKT drafted the article. EV, JRZ, LT, and MH provided critical revision of the article. BKT, EV, KAB, JRZ, CPo, LPa, CP, PM, CH, PP, LT and MH provided final approval for the version submitted for publication.
Corresponding author
Ethics declarations
Conflict of interest
All authors report no conflict of interest relevant to this study.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Tan, B.K., Vivier, E., Bouziad, K.A. et al. A hospital-wide intervention replacing ceftriaxone with cefotaxime to reduce rate of healthcare-associated infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in the intensive care unit. Intensive Care Med 44, 672–673 (2018). https://doi.org/10.1007/s00134-018-5079-y
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-018-5079-y